Company Profile
Zymeworks Inc. is a publicly listed (NYSE: ZYME), clinical-stage, biopharmaceutical company dedicated
to the discovery, development, and commercialization of next-generation multifunctional
biotherapeutics, initially focused on the treatment of cancer. Zymeworks’ suite of complementary
therapeutic platforms and its fully integrated drug development engine provide the flexibility and
compatibility to precisely engineer and develop highly differentiated product candidates.
Zymeworks’ lead product candidate, ZW25, is a HER2-targeted bispecific antibody developed using
Zymeworks proprietary Azymetric™ platform. ZW25 is currently being evaluated in global Phase 1 and
Phase 2 clinical trials as a best-in-class treatment for patients with HER2-expressing cancers,
including biliary tract, gastroesophageal adenocarcinomas, breast, and other tumor types. Zymeworks’
second candidate, ZW49, is a HER2-targeted antibody drug conjugate (ADC) developed using Zymeworks’
proprietary Azymetric™ and ZymeLink™ platforms. ZW49 is currently being evaluated in a Phase 1
clinical trial as a treatment for patients with HER2-expressing cancers.
Zymeworks is also advancing a deep pipeline of preclinical product candidates and discovery-stage
programs in oncology (including immuno-oncology agents) and other therapeutic areas. In addition to
Zymeworks’ wholly owned pipeline, its therapeutic platforms have been further leveraged through
strategic partnerships with global biopharmaceutical companies.